Verastem (VSTM) Gains from Investment Securities (2023 - 2026)
Verastem's (VSTM) quarterly Gains from Investment Securities came in at -$9.3 million in Q1 2026, down 485.89% year-on-year from $2.4 million in Q1 2025, and up 11.08% quarter-over-quarter from -$10.5 million in Q4 2025.
Verastem (VSTM) Gains from Investment Securities (2023 - 2026) Analysis & Trends
Verastem's Gains from Investment Securities history runs 4 years deep, the most recent figure standing at -$9.3 million for Q1 2026.
- On a quarterly basis, Gains from Investment Securities fell 485.89% year-over-year to -$9.3 million in Q1 2026; TTM through Mar 2026 was $15.8 million, a 72.37% decrease from a year earlier, with the FY2025 full-year figure at $27.5 million, up 43.57% from the prior year.
- Gains from Investment Securities rose to -$9.3 million in Q1 2026 per VSTM's latest filing, from -$10.5 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $55.9 million in Q3 2025 and bottomed at -$20.3 million in Q2 2025.
- The 4-year median for Gains from Investment Securities is $5.5 million (2023), against an average of $9.1 million.
- Across the five-year window, Gains from Investment Securities soared 313.93% in 2025 and tumbled 485.89% in 2026, its largest moves.
- Year by year, Gains from Investment Securities stood at $8.5 million in 2023, then jumped by 284.08% to $32.6 million in 2024, then plunged by 132.16% to -$10.5 million in 2025, then increased by 11.08% to -$9.3 million in 2026.
- Per Business Quant, the three latest VSTM Gains from Investment Securities figures stand at -$9.3 million (Q1 2026), -$10.5 million (Q4 2025), and $55.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Verastem | 607.94 Mn | 410.11 Mn | 15.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.32 Mn |
| Mar 31, 2026 | -9.32 Mn |
| Dec 31, 2025 | -10.49 Mn |
| Dec 31, 2025 | -10.49 Mn |
| Sep 30, 2025 | 55.88 Mn |
| Sep 30, 2025 | 55.88 Mn |
| Jun 30, 2025 | -20.32 Mn |
| Jun 30, 2025 | -20.32 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 32.61 Mn |
| Dec 31, 2024 | 32.61 Mn |
| Sep 30, 2024 | 13.50 Mn |
| Sep 30, 2024 | 13.50 Mn |
| Jun 30, 2023 | 8.49 Mn |
| Jun 30, 2023 | 8.49 Mn |